Mark C Markowski (Mark Markowski)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 28

Top Topics

Metastatic Renal Cell Carcinoma

Radical Prostatectomy

Top Venues

Cancer research communications

Nature communications

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Elisabeth I Heath, William Kevin Kelly, Christopher J Hoimes, Pedro C Barata, Jason Taksey, Dominique A Garrison, Kartick Patra, Ginger L Milne, Nicole M Anders, Julie M Nauroth, Jennifer N Durham, Catherine Handy Marshall, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis, Michael A Carducci, Samuel R Denmeade, Mark Levine
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer research communications 4 (8) (2024)
Mark C Markowski, Mary-Ellen Taplin, Rahul R Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Paller, Catherine H Marshall, Mario A Eisenberger, David E Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M DeMarzo, Samuel R Denmeade, Emmanuel S Antonarakis
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature communications 15 (1) (2024)
Catherine Handy Marshall, Lukasz P Gondek, Violet Daniels, Changxue Lu, Sergiu Pasca, Jiajun Xie, Mark C Markowski, Channing J Paller, Laura A Sena, Samuel R Denmeade, Jun Luo, Emmanuel S Antonarakis
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate 84 (10) (2024)
Catherine Handy Marshall, Lukasz P Gondek, Violet Daniels, Changxue Lu, Sergiu Pasca, Jiajun Xie, Mark C Markowski, Channing J Paller, Laura A Sena, Samuel R Denmeade, Jun Luo, Emmanuel S Antonarakis
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate 84 (10) (2024)
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Elisabeth I Heath, William Kevin Kelly, Christopher J Hoimes, Pedro C Barata, Jason Taksey, Dominique A Garrison, Kartick Patra, Ginger L Milne, Nicole M Anders, Julie M Nauroth, Jennifer N Durham, Catherine Handy Marshall, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis, Michael A Carducci, Samuel R Denmeade, Mark Levine
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer research communications 4 (8) (2024)
Mark C Markowski, Mary-Ellen Taplin, Rahul R Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Paller, Catherine H Marshall, Mario A Eisenberger, David E Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M DeMarzo, Samuel R Denmeade, Emmanuel S Antonarakis
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature communications 15 (1) (2024)
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Elisabeth I Heath, William Kevin Kelly, Christopher J Hoimes, Pedro C Barata, Jason Taksey, Dominique A Garrison, Kartick Patra, Ginger L Milne, Nicole M Anders, Julie M Nauroth, Jennifer N Durham, Catherine Handy Marshall, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis, Michael A Carducci, Samuel R Denmeade, Mark Levine
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial. Cancer research communications (2024)
Mark C Markowski, Mary-Ellen Taplin, Rahul R Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Paller, Catherine H Marshall, Mario A Eisenberger, David E Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M DeMarzo, Samuel R Denmeade, Emmanuel S Antonarakis
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature communications 15 (1) (2024)
Mark C Markowski, Mary-Ellen Taplin, Rahul R Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Paller, Catherine H Marshall, Mario A Eisenberger, David E Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M DeMarzo, Samuel R Denmeade, Emmanuel S Antonarakis
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature communications 15 (1) (2024)
Mark C Markowski, Cora N Sternberg, Hao Wang, Tingchang Wang, Laura Linville, Catherine H Marshall, Rana Sullivan, Serina King, Tamara L Lotan, Emmanuel S Antonarakis
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. The oncologist (2024)
Catherine Handy Marshall, Lukasz P Gondek, Violet Daniels, Changxue Lu, Sergiu Pasca, Jiajun Xie, Mark C Markowski, Channing J Paller, Laura A Sena, Samuel R Denmeade, Jun Luo, Emmanuel S Antonarakis
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate (2024)
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Elisabeth I Heath, William Kevin Kelly, Christopher J Hoimes, Pedro C Barata, Jason Taksey, Dominique A Garrison, Kartick Patra, Ginger L Milne, Nicole M Anders, Julie M Nauroth, Jennifer N Durham, Catherine Handy Marshall, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis, Michael A Carducci, Samuel R Denmeade, Mark Levine
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer research communications 4 (8) (2024)
Adel Mandl, Mark C Markowski, Michael A Carducci, Emmanuel S Antonarakis
Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert opinion on investigational drugs (2023)
Rudolf A Werner, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A Lodge, Kenneth J Pienta, Mario A Eisenberger, Mark C Markowski, Michael A Gorin, Martin G Pomper, Steven P Rowe, Ralph A Bundschuh
Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer. The Prostate (2023)
Adel Mandl, Mark C Markowski, Michael A Carducci, Emmanuel S Antonarakis
Role of Bromodomain and Extraterminal (BET) Proteins in Prostate Cancer. Expert opinion on investigational drugs (2023)
Rudolf A Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler, Thorsten Derlin, Takahiro Higuchi, Constantin Lapa, Andreas K Buck, Kenneth J Pienta, Martin A Lodge, Mario A Eisenberger, Mark C Markowski, Martin G Pomper, Michael A Gorin, Eric C Frey, Steven P Rowe, Ralph A Bundschuh
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort. The Prostate 83 (6) (2023)
Rudolf A Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler, Thorsten Derlin, Takahiro Higuchi, Constantin Lapa, Andreas K Buck, Kenneth J Pienta, Martin A Lodge, Mario A Eisenberger, Mark C Markowski, Martin G Pomper, Michael A Gorin, Eric C Frey, Steven P Rowe, Ralph A Bundschuh
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort. The Prostate (2023)
Rudolf A Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler, Thorsten Derlin, Takahiro Higuchi, Constantin Lapa, Andreas K Buck, Kenneth J Pienta, Martin A Lodge, Mario A Eisenberger, Mark C Markowski, Martin G Pomper, Michael A Gorin, Eric C Frey, Steven P Rowe, Ralph A Bundschuh
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort. The Prostate 83 (6) (2023)
Yasser Ged, Mark C Markowski, Nirmish Singla, Steven P Rowe
The shifting treatment paradigm of metastatic renal cell carcinoma. Nature reviews. Urology 19 (11) (2022)
Mark C Markowski, Filip Pirsl, Jeanne C Keruly, Geetanjali Chander, Richard D Moore, Bryan Lau, Corinne E Joshu
Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience. Prostate cancer and prostatic diseases (2022)
Mark C Markowski, Ronald Tutrone, Christopher M Pieczonka, K Gary Barnette, Robert H Getzenberg, Domingo Rodriguez, Mitchell S Steiner, Daniel R Saltzstein, Mario A Eisenberger, Emmanuel S Antonarakis
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (13) (2022)
Samuel R Denmeade, Emmanuel S Antonarakis, Mark C Markowski
Bipolar androgen therapy (BAT): A patient's guide. The Prostate 82 (7) (2022)
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y Song, Arthur Y Hung, Jason W D Hearn, Steven Miller, James A Proudfoot, Matthew P Deek, Ryan Phillips, Tamara Lotan, Channing J Paller, Catherine Handy Marshall, Mark C Markowski, Shirl Dipasquale, Samuel R Denmeade, Michael Carducci, Mario A Eisenberger, Theodore L DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L Liauw, Elisabeth I Heath, Stephen Greco, Neil B Desai, Daniel E Spratt, Felix Y Feng, Hao Wang, Tomasz M Beer, Emmanuel S Antonarakis
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Samuel R Denmeade, Hao Wang, Archana M Agarwal, David C Smith, Michael Thomas Schweizer, Mark N Stein, Vasileios Assikis, Przemyslaw W Twardowski, Thomas W Flaig, Russell Z Szmulewitz, Jeffrey M Holzbeierlein, Ralph J Hauke, Guru P Sonpavde, Jorge A Garcia, Arif Hussain, A Oliver Sartor, Shifeng S Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Cilento, Channing J Paller, Michael A Carducci, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Mark C Markowski, Eugene Shenderov, Mario A Eisenberger, Sushant Kachhap, Drew M Pardoll, Samuel R Denmeade, Emmanuel S Antonarakis
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. The Prostate 80 (5) (2020)
Mark C Markowski, Emmanuel S Antonarakis
PARP inhibitors in prostate cancer: time to narrow patient selection? Expert review of anticancer therapy 20 (7) (2020)
Mark C Markowski, Gretchen K Hubbard, Jessica L Hicks, Qizhi Zheng, Alexia King, David Esopi, Apurv Rege, Srinivasan Yegnasubramanian, Charles J Bieberich, Angelo M De Marzo
Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate 78 (13) (2018)
Mark C Markowski, Angelo M De Marzo, Emmanuel S Antonarakis
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert opinion on investigational drugs 26 (12) (2017)